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Currently, much interest centres on the molecular processes under-
lying the development and progression of transitional cell carcin-
oma of the bladder. It is already clear that molecular pathways
involving the p53 tumour-suppressor gene are of great importance
in bladder cancer, especially the more aggressive types of cancer at
this site (for review see Keegan et al, 1998). 
Fundamental to the neoplastic process is deregulated cellular
proliferation and this will almost certainly be a factor relevant to
the variable biological behaviour of bladder tumours. The cyclin
family of proteins which includes the mitotic cyclins, Aand B, and
cyclins C, D and E (associated with G1/S transition) have a central
role in the control of the cell cycle. They act by binding to specific
catalytic subunits called cyclin-dependent kinases (cdks). One of
the D cyclins, cyclin D1, in complex with cdk4 is essential for
G1/S phase transition and is a major positive regulator of the
critical G1 restriction point in the cell cycle (Sherr, 1996). The
stability of this complex and translocation into the cell nucleus are
regulated by the CKI, waf1/CIP1 protein (Sherr and Roberts,
1999). The cyclin D1-cdk4 complex then initiates phosphorylation
of the retinoblastoma protein (pRb), disrupting its association with
various E2F family members. This then allows transcription of a
number of molecules necessary for DNAsynthesis (Dyson, 1998).
It is also at the G1/S restriction point that wild-type p53, in
response to cell damage, induces the transcription of the WAF1
gene and the resulting p21waf1 protein, a potent cdk inhibitor, binds
and inactivates the cyclin/cdk complexes. This results in accumu-
lation of the active hypophosphorylated pRb, blocking E2F-
dependent transcription leading to cell cycle arrest. 
Amplification of chromosome 11q13 has been found in a variety of
human solid tumours including carcinoma of the bladder (Bringuier
et al, 1996). Of the various genes identified at this position, the gene
encoding cyclin D1 (CCND1) has been identified
as the gene most consistently amplified and overexpressed
(Schuuring et al, 1992). Cyclin D1 was originally isolated as the
PRAD-1 oncogene (Rosenberg et al, 1991) and is known to be
translocated and overexpressed in a significant subset of B-cell
lymphomas. 
A limited number of recent studies have begun to address the
clinical significance of cyclin D1 expression in bladder cancer
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a group of 75 tumours, reported that overexpression of cyclin D1
correlates with early recurrence in Ta/T1 tumours, while in
contrast, Bringuier et al (1996) reported, in a group of 48 tumours
from 46 patients, that tumours with low expression of cyclin D1
have a more aggressive clinical course. 
Few studies, thus far, have examined the complete p53-waf1-
cyclin D1 pathway although, in one reported series of breast
cancers studied in this way, Barbareschi et al (1997) were unable
to find any association between p53, cyclin D1 and the inter-
mediary, waf1. Stein et al (1998) were, however, able to show that
loss of p21 expression was an independent predictor of bladder
cancer progression, while the harmful effects of abnormal p53
were abrogated by maintenance of waf1 expression. We proposed
to investigate the expression of cyclin D1 in a series of human
primary bladder tumours of varying stage and to relate this to clin-
ical outcome as well as to the expression of p53, waf1, pRb and
Ki67, the latter being an established marker of cell proliferation. 
PATIENTS AND METHODS 
This was a retrospective study using formalin-fixed, paraffin-
embedded tumour specimens obtained from 150 patients. All 
specimens had originally been obtained by standard endoscopic
resection from patients with newly diagnosed bladder cancer
between April 1986 and September 1995. Tumours were staged as
defined by UICC criteria and graded according to the WHO classi-
fication. Patient demographics and tumour characteristics are
summarized in Table 1. For those patients with Ta/T1 disease
initially, five patients progressed to muscle-invasive disease and
subsequently died (two who initially had T1G3 disease), five died
of non-bladder cancer-related causes and in two the cause of death
was unknown. For patients with muscle-invasive disease,
25 deaths were due to bladder cancer, two patients died of non-
bladder cancer-related causes and in five the cause was unknown. 
Immunohistochemistry 
Immunohistochemical staining was performed on 5-µm sections
of tumour using a primary monoclonal antibody directed against
cyclin D1 (NCL cyclin D1-GM; Novocastra, Newcastle upon
Tyne, UK). All tumours had previously been stained for p53 using
NCL-DO7 monoclonal antibody (Novocastra) and waf1 using
NCL-WAF1 monoclonal antibody (Novocastra). 54 tumour
sections (Ta/T1 = 28, T2–T4 = 26) were also stained for Ki67
using the monoclonal antibody Ki67-mml (Novocastra) and a
subset of 55 were stained for pRB using NCL-RB1 (Novocastra). 
In staining for cyclin D1, sections were initially dewaxed in
xylene and rehydrated in graded alcohols. Endogenous peroxidase
activity was inhibited by immersing sections in H2O2 (0.3%)
in methanol for 10 min. Antigen retrieval was carried out by
microwaving sections for 15 min at 800 Win 0.01 citrate buffer, pH
6.0. Sections were rinsed twice in tris-buffered saline (TBS) prior to
incubation with normal rabbit serum (10 min at room temperature)
to inhibit non-specific binding. TBS was subsequently used
to wash sections between stages. Sections were then incubated
with cyclin D1 antibody (diluted 1 in 40) for 30 min at room
temperature and after washing, anti-mouse IgG (diluted 1 in 500)
was applied for a further 30 min. Finally, after a further washing step,
streptavidin–biotinylated peroxidase complex (Dako Cambridge Ltd,
UK) was applied (diluted 1 + 1 in 100). Sections were then stained
with diaminobenzidine tetrahydrochloride and counterstained with
haematoxylin. Sections of a mantle-cell lymphoma were used as a
positive control in all staining runs and negative control sections
were duplicate sections in which the primary antibody had been
omitted. Five sections of normal urothelium were also stained for
cyclin D1 using the same technique. 
Assessment of cyclin D1 and Ki67 staining 
The staining patterns for cyclin D1 and Ki67 were assessed by two
independent observers (one a histopathologist) using standard
light microscopy. Nuclear and cytoplasmic staining for cyclin D1
were recorded and both results were used for the purpose of statis-
tical analysis. For each tumour, a cyclin D1 index, defined as the
percentage of cells demonstrating positive nuclear staining after
counting at least 1000 tumour cells at ´ 400 magnification, was
calculated. The intensity of staining was assessed as follows;
no nuclear staining = 0, weak = 1, moderate = 2, strong = 3.
Cytoplasmic staining was recorded as being present or absent.
Nuclear staining alone was recorded for Ki67. For each tumour,
a Ki67 index, defined as the percentage of cells demonstrating
positive nuclear staining after counting at least 1000 tumour cells
at ´ 400 magnification, was calculated. 
Assessment of p53, waf1 and pRb staining 
One thousand cells in the area of highest positivity were scored
using a light microscope (´ 400) to obtain an average percentage
positivity for p53, waf1 and pRb staining. 
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Table 1 Patient and tumour characteristics (n = 150) 
Variable n % 
Age (years) 
Mean (range) 68 (41–91)
Gender 
Male 115 77 
Female 35 23 
Tumour grade 
G1 20 13 
G2 73 49 
G3 57 38 
Tumour classification 
pTa 58 39 
pT1 39 26 
pT2 14 9 
pT3 28 19 
pT4 11 7 
Clinical follow-up (months) 
Median (range) 33 (1–158) 
Lost to follow-up 3 2 
Ta/T1 disease with recurrencea 54 59 
Time to recurrence (months) 
Median (range) 6 (3–74) 
Ta/T1 with progression 9 6 
Time to progression (months) 
Median (range) 34.5 (2–158) 
Deaths 
Ta/T1 12 8 
T2–T4 32 21 
Time to death (months) 
Median (range) 12 (0–86) 
aData concerning recurrence were not available in five patients.Statistical analysis 
The non-parametric Mann–Whitney test was used to assess the
statistical significance of the relationship between the outcome of
staining and tumour stage/grade. The Chi-squared test was used to
assess the correlation of waf1 and cytoplasmic/nuclear cyclin D1
staining. Correlation between data sets was assessed using linear
regression analysis. Survival curves were prepared using the
Kaplan–Meier method with the log-rank test used to compare the
difference between the curves. The multivariate analysis was
performed using a forward stepwise method (Altman, 1991). 
RESULTS 
Immunohistochemical staining for cyclin D1 
Sections of normal urothelium demonstrated nuclear staining in
< 5% of basal cells. Nuclear staining, of variable extent, was identi-
fied in 125 of 150 (83%) sections (Figure 1). On analysing the inten-
sity of staining, 25 specimens (17%) demonstrated absent nuclear
staining, 47 (31%) had weak staining, 61 (41%) had moderate
staining and 17 (11%) had strong staining. The cyclin D1 index
varied widely from 0–100% (median value 38%). The median
cyclin D1 index was significantly higher (41%) in Ta/T1 tumours
compared with 8% for T2–T4 tumours (P < 0.005, Figure 2) with
26% (13 of 53) of T2–T4 tumours demonstrating absent staining. In
addition, the median cyclin D1 index was significantly higher (43%)
in G1/G2 tumours compared with 14% for G3 tumours (P < 0.005,
Figure 2). Intensity of nuclear staining was significantly higher in
Ta/T1 tumours compared with T2–T4 tumours (P < 0.005) and also
significantly higher in G1/G2 tumours compared with G3 tumours
(P < 0.0001). Cytoplasmic staining of varying intensity was found
either in combination with or independent of nuclear staining and
was observed in 30% (15 of 53) of muscle-invasive tumours as well
as 15% (15 of 97) of Ta/T1 tumours (P = 0.60). There was no differ-
ence in the proportion of Ta or T1 tumours with cytoplasmic cyclin
D1 staining(P = 0.26). 
Correlation between cyclin D1, p53, waf1 and pRb 
Using a cut-off level of > 20%, p53 overexpression was found in
53% (28 of 53) of T2–T4 tumours and 37% (37/97) of Ta/T1
tumours. Moreover, only 5% of G1 tumours demonstrated de-
tectable p53 staining as compared with 65% of G3 tumours. A
trend towards an inverse correlation between cyclin D1 and p53
was observed although this was not statistically significant (P =
0.053, Table 2). There was a significant direct correlation between
cyclin D1 and waf1 expression (P < 0.0001, Table 2). When a
distinction was made in the immunolocalization of cyclin D1, we
found a statistically significant correlation between nuclear waf1
staining and nuclear cyclin D1 staining (P = 0.0011, Table 3). pRb
staining was studied in 55 cases with median values for Ta/T1 and
T2–T4 tumours being 62.5% and 70% respectively. There was a
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Figure 1 (A) TaG1 tumour demonstrating diffuse nuclear cyclin D1 staining (´ 100). (B) The same tumour shown at higher magnification (´ 400). (C) Section
from muscle-invasive tumour demonstrating strong cytoplasmic staining (´ 100). (D) As C shown at higher magnification (´ 200) direct correlation between pRb and cyclin D1 in the study group as
a whole (n = 55, P < 0.05, Table 2), but such a correlation was not
apparent for muscle-invasive tumours when analysed separately
(P = 0.507). 
Ki67 immunostaining 
Nuclear staining for Ki67 was of variable extent with a median
value of 39% positively staining tumour nuclei (range 0–95%).
Only one tumour (2%) did not stain for Ki67. The median Ki67
score was significantly lower (33%) in Ta/T1 tumours compared
with 51% for T2–T4 tumours (P < 0.005). Ki67 expression
was also significantly associated with increasing tumour grade
(P < 0.05). There was no correlation between cyclin D1 expression
and Ki67 expression (P > 0.05, Table 2). 
Cyclin D1 and clinical outcome 
Cyclin D1 expression was assessed in relation to tumour recurrence,
stage progression and overall survival. No correlation was found
between nuclear cyclin D1 staining and tumour recurrence or
progression, however, patients with muscle-invasive disease with a
cyclin D1 index of < 8% had significantly reduced survival
compared with those with an index of ³ 8% (P = 0.011, Figure 3). In
a multivariate analysis comparing cyclin D1, p53 and tumour grade,
cyclin D1 expression was found to be an independent prognostic
indicator of survival (P = 0.019). There was no correlation between
cytoplasmic staining for cyclin D1 and survival for those patients
with muscle-invasive disease. In patients with Ta/T1 disease, there
was no difference in recurrence rates between patients with cyto-
plasmic staining and those who had none. There was, however, a
significant correlation between cytoplasmic staining for cyclin D1
and progression for patients with Ta/T1 disease (P= 0.045, Figure 4). 
DISCUSSION 
In this study, we found cyclin D1 expression was significantly
higher in low-stage, well differentiated bladder tumours. This
finding is in agreement with Lee and colleagues who have reported
overexpression of cyclin D1 in association with papillary, low-
grade, non-invasive bladder tumours (Lee et al, 1997). As a conse-
quence, one current hypothesis is that more aggressive, invasive
tumours progress via a biological pathway independent of cyclin
D1. To support this, Bringuier et al (1996) found that tumours with
low expression of cyclin D1 were all highly aggressive. It is
possible that more invasive tumours display cyclin D1 overexpres-
sion at an earlier stage in their natural history or that invasive
tumours do not overexpress cyclin D1. In contrast to our study, a
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Figure 2 Cyclin D1 expression for tumour stage/grade 
Table 2 Relationship between cyclin D1 expression and waf1, p53, pRb
and Ki67 expression 
Cyclin D1 r value P value 
Waf1 0.33 0.000011 
p53 20.19 0.059
pRb 0.22 0.031 
Ki67 0.05 n.s. 
r = correlation coefficient; n.s. = not significant.
Table 3 Relationship between waf1 and cyclin D1 expression (nuclear vs
cytoplasmic) 
wafl 
Low < 37%a High ³ 37% 
Cyclin D1 
Cytoplasmic 24 6
Nuclear 56 64 
P = 0.0011.
a37% = median waf1 score.
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recent study of bilharzial bladder cancer reported a significant
association between a cyclin D1-positive phenotype and deep
muscle invasion/high tumour grade (Osman et al, 1997), although
this group included squamous cell and adenocarcinomas of the
bladder which may be different from the much commoner transi-
tional cell histology. 
In our series, 52% of tumours demonstrated overexpression of
cyclin D1, in agreement with Shin et al (1997) who, in a smaller
number of tumours, found overexpression in approximately 50%
of tumours. Despite these data, the frequency of amplification
of 11q13 in bladder tumours is only approximately 10–15%
(Schuuring, 1995; Bringuier et al, 1996). Thus, cyclin D1 amplifi-
cation is unlikely to account for the observed high rates of protein
overexpression. It may be that overexpression is caused by mech-
anisms other than amplification, such as a mutation in the gene
promoter region, post-transcriptional events or alterations of a
regulatory transcription factor (Gillett et al, 1994). 
An unexpected finding was the immunohistochemical localiza-
tion of cyclin D1. We found cytoplasmic staining of varying inten-
sity, either alone or in combination with nuclear staining in 30%
of muscle-invasive tumours and in 15% of Ta/T1 tumours. This
staining correlated with progression in those patients with Ta/T1
disease, however, we were unable to find any further relationship
between this finding and clinical outcome. This finding has also
been reported in a recent immunohistochemical study of cyclin D1
in transitional cell carcinoma by Suwa et al (1998). One possible
explanation is that cyclin D1 or its related cdk may be inactivated
by being bound to further substrates in more aggressive tumours
and as a consequence loses its nuclear localization. Another
possible explanation is that there may be inactivation of waf1,
which normally localizes cyclin D1 complexes to the nucleus. 
The significance of overexpression of cyclin D1 in relation to
prognosis has now been reported in a number of tumours including
adenocarcinoma of the pancreas, breast carcinoma and squamous
cell carcinoma of the head and neck, with, in contrast to our study,
high levels of cyclin D1 expression related to poor prognosis. In
addition, Ishikawa et al (1998) most recently noted that patients with
squamous cell carcinoma of the oesophagus who were cyclin 
D1-positive had a worse prognosis than those who were cyclin D1-
negative. 
Previously, in vitro studies have demonstrated that p53 induces
cyclin D1, a mechanism at least partially mediated by waf1 and
pRb (Chen et al, 1995). Despite this, Barbareschi et al (1997) were
unable to find any association between p53, waf1 and cyclin D1
amplification/overexpression in 64 breast carcinomas. Our data
are in keeping with the in vitro model, with not only a significant
correlation between cyclin D1 and wafl expression, but moreover,
a noticeable trend towards a negative correlation between cyclin
D1 and abnormal p53. There are a number of possible reasons for
the significant correlation between cyclin D1 and wafl. It has been
reported that overexpression of cyclin D1 promotes cell cycle
progression and differentiation, generally observed as shortened
G1/S transition and oncogenesis (Sherr, 1994). However, it has
also been shown that cyclin D1 levels may be raised in growth-
arrested cells. Pagano et al (1994) noted that an increase in cyclin
D1 levels in fibroblasts led to growth arrest, and similarly Dulic et
al (1993) have reported increased levels of non-functional cyclin
D1 in senescent cells. Cyclin D1 may, therefore, have a dual role
in growth promotion and growth arrest and in fact may reflect
wild-type p53 status. Wafl may also have a dual role and the WAF1
gene has been shown to be induced through a p53-independent
mechanism following stimulation with purified growth factors
or serum (Liu et al, 1996). In support of this, Zhang et al
(1994) found most waf1 is located in activated cyclin/cdk
complexes present in proliferating cells. More recently, it has been
demonstrated that ectopic expression of cyclin D1 correlated with
increased levels of waf1 which did not lead to growth arrest
(Hiyama et al, 1997). In keeping with this finding, it has also been
shown that, in contrast to cyclin E–cdk complexes, waf1 has a
significant role in cyclin D–cdk complex assembly and transloca-
tion into the cell nucleus and also appears to stabilize the higher
order complexes (Sherr and Roberts, 1999). 
The retinoblastoma gene (Rb) encodes a 110 kDa nuclear
protein (pRb) which is a target for phosphorylation by cyclin–cdk
complexes (DeCaprio et al, 1989). Moreover, pRb has a central
role in the control of cellular proliferation by regulating the G1/S
transition of the cell cycle (Weinberg, 1995). In early G1 and G0,
the protein is found in its hypophosphorylated, active form. As
cells progress into late G1 and early S phase, pRb becomes highly
phosphorylated by the cyclin–cdk complexes and remains in its
phosphorylated state in the G2 phase. Phosphorylation of Rb
proteins inhibits their ability to bind and inactivate a family of
transcription factors (E2F family) which regulate the expression of
genes important for cell proliferation and DNA replication (e.g.
dihydrofolate reductase, thymidylate synthase and cyclins A and
E). Recently it has been suggested that the low incidence of cyclin
D1 expression in high-grade bladder cancer may be due to loss of
function of the Rb gene. Anumber of recent studies have indicated
that Rb is capable of regulating cyclin D1 (Lukas et al, 1994;
Muller et al, 1994). Rb is mutated or deleted in a wide array of
human tumours, implying that it exerts its growth regulatory
effects in a wide range of tissues. Recently, a number of groups
have shown that alterations of both p53 and pRb have a coopera-
tive negative effect in progression and survival in bladder cancer
(Cote et al, 1998; Grossman et al, 1998). 
In conclusion, we found that cyclin D1 expression was signifi-
cantly higher in low-stage, well differentiated tumours and is an
independent prognostic indicator for survival of patients with
T2–T4 stage tumours. The significant association between cyclin
D1 and waf1 may be a reflection of p53 status and further studies
will be required to assess the functional significance of this. 
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